Added to YB: 2025-12-30
Pitch date: 2025-12-29
DVYSR.ST [bullish]
Devyser Diagnostics AB (publ)
Author Info
No bio for this author
Company Info
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia.
Market Cap
SEK 1.9B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
172.39
P/E
-74.48
EV/Sales
7.67
Sector
Biotechnology
Category
growth
The portfolio I am taking into 2026 - Devyser Diagnostics AB
DVYSR.ST: Swedish NGS diagnostics co targeting hereditary diseases, oncology, transplant medicine. FDA-approved IVD test kit could revolutionize US transplant monitoring, turning hospitals from cost to profit centers, potentially 20x revenue growth. 2026: 45x PE, 5.4x EV/Sales; 2027: 24x PE, 4.2x EV/Sales.
Read full article (1 min)